Curing disease not a “sustainable business model,” Goldman Sachs analysts say

Enlarge / The Goldman Sachs bank logo is seen reflected on the screen of a mobile phone in this photo illustration on November 15, 2017. (credit: Jaap Arriens/NurPhoto via Getty Images)

One-shot cures for diseases are not great for business—more specifically, they’re bad for longterm profits—Goldman Sachs analysts noted in an April 10 report for biotech clients, first reported by CNBC.

The investment banks’ report, titled “The Genome Revolution,” asks clients the touchy...

What feeling does this article give you?

#hashtags to follow:

Goldman Sachs [+]    November 15 [+]    Jaap Arriens [+]    NurPhoto [+]    Getty Images [+]    April 10 [+]    CNBC [+]    Genome Revolution [+]   

More #news: